News Releases
Mar 6 2002
Avid Bioservices Enters Into a Manufacturing and Supply Agreement With Seradyn
Mar 4 2002
Peregrine Announces Grant of Patent for New Class of Vascular Targeting Agents
Feb 28 2002
Peregrine and OXiGENE Conclude Arcus Therapeutics LLC Joint Venture; Companies Reacquire Full Rights to Respective Vascular Targeting Technologies
Feb 4 2002
Peregrine Pharmaceuticals Announces $2.2 Million Investment From Institutional Investors
Jan 29 2002
Peregrine Pharmaceuticals Announces Grant of Patent for New Anti-Cancer Antibodies
Jan 8 2002
Peregrine Pharmaceuticals Announces Formation of Contract Manufacturing Subsidiary Avid Bioservices Inc.
Dec 20 2001
Peregrine Pharmaceuticals Announces the Initiation of Human Antibody Generation Against Two Additional Antigen Targets With Xenerex Biosciences
Dec 17 2001
Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Similar Characteristics of Chimeric and Human TNT Monoclonal Antibodies
Dec 17 2001
Peregrine Announces Quarterly Conference Call
Dec 13 2001
Peregrine Pharmaceuticals Announces It has Agreed Upon the Design of a Phase III Study for Brain Cancer With the FDA; Study Will Treat Patients With Recurrent Glioblastoma Multiforme